Pulse cyclophosphamide therapy for refractory adult-onset Still's disease / 中国实用内科杂志

ABSTRACT

Objective To study the efficacy and safety of pulse cyclophosphamide(CTX)therapy for refractory adult-onset Still's disease(AOSD).Methods Eleven patients with refractory AOSD received the treatment of intravenous pulse cyclophosphamide with 500～750 mg/m2 body surface area.The features of clinical manifestations and lab findings before and after the treatment were compared.The literatures associated with pulse CTX therapy were reviewed.Results After the first time of pulse CTX therapy,nine cases returned body temperature to normal within 72 hours,and the other two within 1week.Fever relapse was seen in five patients after the first time of pulse CTX therapy,and they returned body temperature to persistent normal after the second time of pulse CTX therapy.At the point of 1 week after the first time of pulse CTX therapy,serum C-reactive protein(CRP)significantly decreased when compared with that before treatment(P